What is VTRS stock price today?

VTRS (Viatris Inc) stock is trading at $13.37 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is VTRS stock going up or down today?

VTRS stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy VTRS stock now?

The decision to buy VTRS depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is VTRS a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for VTRS based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is VTRS stock overvalued or undervalued?

Use our DCF valuation calculator to determine if VTRS is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is VTRS's P/E ratio?

P/E ratio data for VTRS will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is VTRS's market cap?

VTRS (Viatris Inc) has a market capitalization of $14.64 billion, making it a mid-cap stock.

What is VTRS's price to book ratio?

VTRS trades at a price-to-book (P/B) ratio of 0.96, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does VTRS pay dividends?

Yes, VTRS pays dividends with a current yield of 0.04%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is VTRS's dividend yield?

VTRS's dividend yield is 0.04%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is VTRS stock a good long-term investment?

VTRS's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is VTRS's revenue growth rate?

VTRS has shown revenue growth of 0.0% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

VTRS is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in VTRS?

Key risks for VTRS include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does VTRS compare to its competitors?

Compare VTRS to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize VTRS's performance and positioning.

What is VTRS's stock price target for 2026?

Our AI model provides price targets for VTRS based on fundamental analysis: Bull case $17.38 (+30%), Base case $15.38 (+15%), Bear case $12.03 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about VTRS?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for VTRS. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is VTRS's next earnings report?

VTRS reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

VTRS - Viatris Inc

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$13.37

+$0.69 (+5.44%)

About Viatris Inc

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

VTRS Key Statistics

Market Cap

$14.64B

P/B Ratio

0.96

EPS

$-3.13

Dividend Yield

0.04%

Revenue Growth

+0.0%

Profit Margin

-0.3%

Employees

30,000

How VTRS Compares to Peers

VTRS is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Rev Growth	Margin	Compare
VTRS(This stock)	$14.64B	N/A	0.0%	-0.3%	-
LLYEli Lilly	$969.07B	52.9	0.5%	0.3%	vs LLY
JNJJohnson &	$505.28B	20.2	0.1%	0.3%	vs JNJ
PFEPfizer Inc	$143.68B	14.7	-0.1%	0.2%	vs PFE
MRKMerck &	$272.73B	14.4	0.0%	0.3%	vs MRK
ABBVAbbvie Inc	$388.90B	166.7	0.1%	0.0%	vs ABBV

Viatris Inc Company Information

Headquarters: Robert J. Coury Global Center, Canonsburg, PA, United States, 15317, undefined
Website: www.viatris.com
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

VTRS - Viatris Inc

About Viatris Inc

VTRS Key Statistics

How VTRS Compares to Peers

Viatris Inc Company Information

VTRS Lician Score

VTRS Financial Snowflake

Upcoming Events for VTRS